Lotus Ventures Inc (CSE:J) or (the “Company”) met with David Hyde & Associates last week to discuss the final steps prior to submitting its evidence package to Health Canada. The overall impact of the meeting was positive, as security is a large portion of the package. 100 on-site security cameras, perimeter fencing and the production vault have all been installed and are operational.

Lotus set an anticipated date with Mr. Hyde and his team, to return to the facility in December to film and finalize the evidence package. The package can then be edited and submitted to Health Canada and the Lotus cultivation license should be issued shortly thereafter.


O’Cannabiz and Lift & Co. Expo Vancouver

A portion of the Lotus team will be attending both O’Cannabiz Expo (December 10-11) and the Lift & Co. Cannabis Expo (January 10-13) in Vancouver, BC. The team invites shareholders to attend, as this will be a great opportunity to discuss the company’s strategy and plans for 2019.

ON BEHALF OF THE BOARD
Lotus Ventures Inc.
“Dale McClanaghan”
Dale McClanaghan, President and CEO

About Lotus Ventures Inc.
Lotus is a late stage licensed producer applicant under the Cannabis Act, in active review with Health Canada. The unique business model combines an upstream royalty financing model with Auxly and a downstream licensing model with farmer/grower partners using Lotus technology and intellectual property. The first facility in Spallumcheen, B.C. is a purpose built, “state of the art” indoor facility with proprietary processes.

For further information: Dale McClanaghan: dalemcclanaghan@gmail.com(604) 644-9844 or Daniel McRobert, Communications danielmcrobertt@gmail.com (604) 842-4625

Click here to connect with Lotus Ventures Inc (CSE:J) for an Investor Presentation. 

Source: www.lotusventures.ca

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less